NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix Inc.'s Rare Disease Therapies and BioMedWire Editorial Feature
TL;DR
Soligenix's late-stage HyBryte therapy for CTCL offers investors potential advantage in the growing rare disease market with over 30 million Americans affected.
Soligenix develops HyBryte using synthetic hypericin sodium photodynamic therapy, with Phase 3 trials completed and regulatory approvals sought for CTCL treatment.
Soligenix's rare disease therapies address unmet medical needs for millions, improving lives through innovative treatments for conditions like CTCL and inflammatory diseases.
Soligenix's heat stabilization platform ThermoVax preserves vaccine potency, supporting development for ricin, filoviruses, and COVID-19 with government funding.
Found this article helpful?
Share it with your network and spread the knowledge!
The editorial examines the urgent rise of chronic and rare diseases in aging populations and the growing demand for novel therapies, with Soligenix highlighted as a company advancing late-stage rare disease treatments.
Over 30 million Americans live with rare disorders that often lack FDA-approved treatments, creating significant unmet medical needs that Soligenix's therapies aim to address.
HyBryte™ (SGX301 or synthetic hypericin sodium) is Soligenix's novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), currently in its final confirmatory trial.
Beyond HyBryte™, Soligenix is developing synthetic hypericin (SGX302) for psoriasis, dusquetide (SGX942) for inflammatory diseases including oral mucositis, and SGX945 for Behçet's Disease, along with first-in-class innate defense regulator technology.
Soligenix is developing RiVax® (ricin toxin vaccine), vaccines targeting filoviruses like Marburg and Ebola, and CiVax™ for COVID-19 prevention, all incorporating the proprietary ThermoVax® heat stabilization platform technology.
This segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
BioMedWire is a specialized communications platform focusing on Biotechnology, Biomedical Sciences, and Life Sciences developments, and it featured Soligenix in an editorial about rare disease therapies due to the company's relevant late-stage programs.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
HyBryte™ is now in its final confirmatory trial, and with successful completion of the second Phase 3 study, Soligenix will seek regulatory approvals to support potential worldwide commercialization.
Curated from InvestorBrandNetwork (IBN)
